AR034392A1 - Compuestos derivados de 3, 16-dihidroxi-estra-1,3,5(10)-trieno, empleo de los mismos y de partes estructurales de los mismos y composiciones farmaceuticas que los contienen - Google Patents
Compuestos derivados de 3, 16-dihidroxi-estra-1,3,5(10)-trieno, empleo de los mismos y de partes estructurales de los mismos y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR034392A1 AR034392A1 ARP000100553A ARP000100553A AR034392A1 AR 034392 A1 AR034392 A1 AR 034392A1 AR P000100553 A ARP000100553 A AR P000100553A AR P000100553 A ARP000100553 A AR P000100553A AR 034392 A1 AR034392 A1 AR 034392A1
- Authority
- AR
- Argentina
- Prior art keywords
- alpha
- beta
- beta position
- unsaturated
- saturated
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 12
- 125000004432 carbon atom Chemical group C* 0.000 abstract 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 4
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 102000015694 estrogen receptors Human genes 0.000 abstract 2
- 108010038795 estrogen receptors Proteins 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- -1 methoxy, ethoxy atom Chemical group 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- DVMAUGGKVWJBDV-COMOZRQASA-N (8s,9s,13r,14s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16-diol Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC(O)C[C@@]1(C)CC2 DVMAUGGKVWJBDV-COMOZRQASA-N 0.000 abstract 1
- DVMAUGGKVWJBDV-FXXCCUJSSA-N (8s,9s,13r,14s,16r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16-diol Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1C[C@@H](O)C[C@@]1(C)CC2 DVMAUGGKVWJBDV-FXXCCUJSSA-N 0.000 abstract 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 abstract 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010030247 Oestrogen deficiency Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 abstract 1
- 230000001143 conditioned effect Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- DVMAUGGKVWJBDV-IREHDKGXSA-N estra-1,3,5(10)-triene-3,16beta-diol Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1C[C@H](O)C[C@@]1(C)CC2 DVMAUGGKVWJBDV-IREHDKGXSA-N 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
- 150000003462 sulfoxides Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 210000004291 uterus Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0055—Estrane derivatives not substituted in position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen nuevos compuestos derivados del 3,16-dihidroxi-estra-1,3,5(10)-trieno, de fórmula general (1) en la que los restos R1 a R17, independientemente entre sí, poseen los siguientes significados: R1 es un átomo de halógeno, hidroxilo, metilo, trifluormetilo, metoxi, etoxi o un átomo de hidrógeno; R2 es un átomo de halógeno, hidroxilo, alcoxi con hasta 6 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, o un átomo de hidrógeno; R4 es un átomo de halógeno, alquilo con hasta 10 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, trifluormetilo o pentafluoretilo, alcoxi con hasta 6 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, o un átomo de hidrógeno; un átomo de halógeno en posición alfa o beta, alquilo en posición alfa o beta, con hasta 10 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, en casos dados, parcial- o totalmente fluorado, alcoxi con hasta 6 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, un resto arilo o heteroarilo, en casos dados, sustituido, o un átomo de hidrógeno; R8 es un átomo de hidrógeno en posición alfa o beta, alquilo en posición alfa o beta, con hasta 10 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, en casos dados, parcial- o totalmente fluorado, o ciano en posición alfa o beta; R9 es un átomo de hidrógeno en posición alfa o beta, metilo, etilo, trifluormetilo o pentafluoretilo en posición alfa o beta; R11 es nitrooxi en posición alfa o beta, hidroxilo o mercapto en posición alfa o beta, un átomo de halógeno en posición alfa o beta, clorometilo en posición alfa o beta, alquilo en posición alfa o beta, con hasta 10 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, en casos dados, parcial- o totalmente fluorado, alcoxi o alquiltio con hasta 6 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, un resto arilo o heteroarilo, en casos dados, sustituido, o un átomo de hidrógeno; R13 es metilo, etilo, trifluormetilo o pentafluoretilo en posición alfa o beta y R14 es alquilo en posición alfa o beta, con hasta 10 átomos de carbono de cadena lineal o ramificada, saturado o insaturado, en casos dados, parcial- o totalmente fluorado, o un átomo de hidrógeno en posición alfa o beta; y R15 es un átomo de halógeno en posición alfa o beta, alquilo en posición alfa o beta, con hasta 10 átomos de carbono que puede estar interrumpido con uno o varios átomos de oxígeno, azufre, o con uno o varios grupos sulfóxido, sulfónicos o imino =NR15' (R15' = átomo de hidrógeno, metilo, etilo, propilo, i-propilo), de cadena lineal o ramificada, saturado o insaturado, en casos dados, parcial- o totalmente fluorado, o un átomo de hidrógeno; o R14 y R15, en conjunto, un grupo 14alfa-15alfa-metileno o 14beta-15beta-metileno, en casos dados, sustituidos con uno o dos átomos de halógeno; R16 es alquilo en posición alfa o beta, con hasta 10 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, en casos dados, parcial- o totalmente fluorado, trifluormetilo o pentafluoretilo, cianometilo o un átomo de hidrógeno en posición alfa o beta; R17 es un átomo de halógeno en posición alfa o beta, alquilo en posición alfa o beta, con hasta 10 átomos de carbono, de cadena lineal o ramificada, saturado o insaturado, en casos dados, parcial- o totalmente fluorado, un átomo de hidrógeno o hidroxilo; así como las líneas intermitentes ----- en los anillos B, C y D, significan en casos dados, uno o más dobles enlaces, y las líneas onduladas - - - - significan la disposición de los sustituyentes considerados en la posición alfa o beta, exceptuando los compuestos estra-1,3,5(10)-trien-3,16alfa-diol, estra-1,3,5(10)-trien-3,16beta-diol, estra-1,3,5(10),7-tetraen-3,16alfa-diol, así como el estra-1,3,5(10),7-tetraen-3,16beta-diol, 16alfa-etinil-estra-1,3,5(10)-trien-3,16beta-diol y 16beta-etinil-estra-1,3,5(10)-trien-3,16alfa-diol. Estos compuestos son estrógenos esteroides selectivos según el tejido, los que presentan, in vitro, una mayor afinidad por las preparaciones de receptores de estrógeno de próstata de rata que por las preparaciones de receptores de estrógeno de útero de rata e, in vivo, una acción preferencial en huesos, en comparación con la desarrollada en el útero, y/o una acción pronunciada desde el punto de vista de la estimulación de la expresión del receptor 5HT2a y el transportador 5HT2a. También se describen las composiciones farmacéuticas que contienen estos compuestos, así como el empleo de estos últimos para tratar enfermedades y estados condicionados por la deficiencia de estrógenos en la mujer y en el hombre.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906159A DE19906159A1 (de) | 1999-02-09 | 1999-02-09 | 16-Hydroxyestratriene als selektiv wirksame Estrogene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034392A1 true AR034392A1 (es) | 2004-02-25 |
Family
ID=7897485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000100553A AR034392A1 (es) | 1999-02-09 | 2000-02-09 | Compuestos derivados de 3, 16-dihidroxi-estra-1,3,5(10)-trieno, empleo de los mismos y de partes estructurales de los mismos y composiciones farmaceuticas que los contienen |
Country Status (30)
| Country | Link |
|---|---|
| EP (2) | EP1580192A2 (es) |
| JP (1) | JP2002536455A (es) |
| KR (1) | KR20010101822A (es) |
| CN (1) | CN1346364A (es) |
| AR (1) | AR034392A1 (es) |
| AT (1) | ATE313553T1 (es) |
| AU (1) | AU2909500A (es) |
| BG (1) | BG105804A (es) |
| BR (1) | BR0008076A (es) |
| CA (1) | CA2359660A1 (es) |
| CO (1) | CO5150223A1 (es) |
| CZ (1) | CZ20012843A3 (es) |
| DE (2) | DE19906159A1 (es) |
| DK (1) | DK1144431T3 (es) |
| EA (1) | EA200100828A1 (es) |
| EE (1) | EE200100412A (es) |
| ES (1) | ES2255983T3 (es) |
| HK (1) | HK1046145A1 (es) |
| HU (1) | HUP0200055A3 (es) |
| IL (1) | IL144455A0 (es) |
| MX (1) | MXPA01008065A (es) |
| NO (1) | NO20013860L (es) |
| NZ (1) | NZ513409A (es) |
| PE (1) | PE20001461A1 (es) |
| PL (1) | PL350360A1 (es) |
| PT (1) | PT1144431E (es) |
| SK (1) | SK11302001A3 (es) |
| WO (1) | WO2000047603A2 (es) |
| YU (1) | YU57201A (es) |
| ZA (1) | ZA200107388B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10039199A1 (de) * | 2000-08-10 | 2002-02-21 | Schering Ag | Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen |
| DE10048634A1 (de) * | 2000-09-27 | 2002-04-18 | Jenapharm Gmbh | 19-Nor-17alpha-pregna-1,3,5(10)-trien-17beta-ole mit einem 21, 16alpha-Laktonring |
| DE10151365A1 (de) | 2001-10-17 | 2003-04-30 | Schering Ag | 17-Chlor-D-Homosteroide als selektive Estrogenrezeptorantagonisten |
| DE10151114A1 (de) * | 2001-10-15 | 2003-04-17 | Schering Ag | 8ß-Substituierte-11ß-aryl-estra-2,3,5(10)-trienderivate |
| DE10151363A1 (de) * | 2001-10-17 | 2003-05-08 | Schering Ag | Somatotrope Therapie |
| US7414043B2 (en) | 2002-06-11 | 2008-08-19 | Schering Ag | 9-α-substituted estratrienes as selectively active estrogens |
| DE10226326A1 (de) * | 2002-06-11 | 2004-01-15 | Schering Ag | 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene |
| TWI392682B (zh) * | 2006-04-13 | 2013-04-11 | Sigma Tau Ind Farmaceuti | 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物 |
| TWI389917B (zh) * | 2006-04-13 | 2013-03-21 | Sigma Tau Ind Farmaceuti | 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物 |
| SE536263C2 (sv) * | 2011-12-21 | 2013-07-23 | Airqone Building Scandinavia Ab | Reningsanordning för gasmedium innefattande medel för kontrollerad tillförsel av joniserad luft |
| CN109937044A (zh) * | 2016-08-22 | 2019-06-25 | 奥诊科治疗公司 | 雌激素受体β选择性配体 |
| WO2019041078A1 (en) * | 2017-08-28 | 2019-03-07 | Zhejiang Jiachi Pharmaceutical Development Ltd. | ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES |
| US11512107B2 (en) | 2018-09-07 | 2022-11-29 | Trustees Of Dartmouth College | Methods for assembly of tetracyclic compounds by stereoselective C9-C10 bond formation |
| AU2019335005A1 (en) * | 2018-09-07 | 2021-03-18 | Trustees Of Dartmouth College | C19 scaffolds and steroids and methods of use and manufacture thereof |
| CN115154474A (zh) * | 2021-04-01 | 2022-10-11 | 中国人民解放军总医院 | 一种环菠萝蜜烷型三萜皂苷化合物在制备t细胞免疫抑制剂中的应用 |
| CN121129864A (zh) * | 2025-11-17 | 2025-12-16 | 浙江大学 | 麦角甾醇在制备治疗肺动脉高压药物中的应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3079408A (en) * | 1963-02-26 | Ig-bisoxygenated iy-haloestra- | ||
| US3103524A (en) * | 1963-09-10 | Ratetraene- | ||
| GB823955A (en) * | 1955-09-01 | 1959-11-18 | Nepera Chemical Co Inc | Improvements in steroid compounds and method for manufacture of same |
| GB804789A (en) * | 1956-02-06 | 1958-11-26 | Searle & Co | 16-alkylestratriene-3,16,17-triols and derivatives thereof |
| US2779773A (en) * | 1956-05-23 | 1957-01-29 | Nepera Chemical Co Inc | Steroid 3, 16alpha-diols and process |
| US3166473A (en) * | 1962-04-12 | 1965-01-19 | Mochida Pharm Co Ltd | New esters of 1, 3, 5-estratriene-3, 16, 17-triol and novel pharmaceutical compositions containing new esters of 1, 3, 5-estratriene-3, 16, 17-triol and esters of 1, 3, 5-estratriene-3, 16, 17-triol |
| NL124324C (es) * | 1964-01-24 | |||
| FR4339M (es) * | 1965-03-29 | 1966-08-08 | ||
| FR5099M (es) * | 1966-01-12 | 1967-05-22 | ||
| US3449383A (en) * | 1967-02-16 | 1969-06-10 | Searle & Co | 17-oxygenated estra-1,3,5(10)-triene-3,11beta,16-triols,ethers and esters thereof |
| US3470159A (en) * | 1967-07-13 | 1969-09-30 | American Home Prod | Estra-1,3,5(10),7-tetraenes and process of preparation |
| CH538460A (de) * | 1969-02-27 | 1973-06-30 | Ciba Geigy Ag | Verfahren zur Herstellung eines neuen hochwirksamen Östratriols |
| CH537915A (de) * | 1969-02-27 | 1973-06-15 | Ciba Geigy Ag | Verfahren zur Herstellung eines neuen Östratriols |
| US3600705A (en) * | 1969-02-27 | 1971-08-17 | Gen Electric | Highly efficient subcritically doped electron-transfer effect devices |
| GB1235642A (en) * | 1969-02-27 | 1971-06-16 | Ciba Geigy | A new oestratriol and a process for its manufacture |
| FR2034569B1 (es) * | 1969-02-27 | 1973-07-13 | Ciba Geigy Ag | |
| US3622670A (en) * | 1969-08-22 | 1971-11-23 | American Home Prod | Method of inducing ovulation |
| IL38806A0 (en) * | 1971-03-05 | 1972-04-27 | Ciba Geigy Ag | Pharmaceutical compositions comprising estrogens and anthracene derivatives |
| US3766224A (en) * | 1971-06-03 | 1973-10-16 | Sandoz Ag | 15-methyl-substituted steroids |
| US3946052A (en) * | 1975-06-16 | 1976-03-23 | Stanford Research Institute | 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity |
| JPS5265259A (en) * | 1975-11-27 | 1977-05-30 | Takeda Chem Ind Ltd | Synthesis of 16beta-alkylestradiol or its 17-esters |
| NL7613248A (nl) * | 1976-11-26 | 1978-05-30 | Akzo Nv | Werkwijze voor het bereiden van nieuwe steroid- esters. |
| DD145919B1 (de) * | 1978-06-28 | 1982-06-30 | Kurt Ponsold | Verfahren zur herstellung von 14,1 -methylenderivaten der oestranreihe |
| SE8305596D0 (sv) * | 1983-10-12 | 1983-10-12 | Leo Ab | A selective acylation method |
| DE3510555A1 (de) * | 1985-03-21 | 1986-09-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | Estriolester |
| US4705783A (en) * | 1985-06-25 | 1987-11-10 | Sri International | 9α, 11β-substituted and 11β-substituted estranes |
| HU208150B (en) * | 1988-10-31 | 1993-08-30 | Endorecherche Inc | Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives |
| SU1761760A1 (ru) * | 1990-07-02 | 1992-09-15 | Всесоюзный Эндокринологический Научный Центр Амн Ссср | Способ получени 11-нитратов 9 @ , 11 @ -диоксистероидов |
| DE4239946C2 (de) * | 1992-11-27 | 2001-09-13 | Jenapharm Gmbh | Estranderivate mit einer 14alpha,15alpha-Methylengruppe und Verfahren zu ihrer Herstellung |
| DE4322186A1 (de) * | 1993-07-03 | 1995-01-12 | Jenapharm Gmbh | Oral estrogen wirksame Ester des 14alpha, 15alpha-Methylen-estradiols |
| DE4326240A1 (de) * | 1993-08-02 | 1995-02-09 | Schering Ag | 15,15-Dialkyl-substituierte Derivate des Estradiols |
| US5554603A (en) * | 1993-09-17 | 1996-09-10 | The United States Of America As Represented By The Department Of Health And Human Services | Orally active derivatives of 1,3,5(10)-estratriene |
| DE4338314C1 (de) * | 1993-11-10 | 1995-03-30 | Jenapharm Gmbh | Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen |
| SE9502921D0 (sv) * | 1995-08-23 | 1995-08-23 | Astra Ab | New compounds |
| DE19635525A1 (de) * | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE19815060A1 (de) * | 1998-04-03 | 1999-10-14 | Jenapharm Gmbh | Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie |
-
1999
- 1999-02-09 DE DE19906159A patent/DE19906159A1/de not_active Withdrawn
-
2000
- 2000-02-08 CO CO00007990A patent/CO5150223A1/es unknown
- 2000-02-08 PE PE2000000093A patent/PE20001461A1/es not_active Application Discontinuation
- 2000-02-09 IL IL14445500A patent/IL144455A0/xx unknown
- 2000-02-09 EP EP05075149A patent/EP1580192A2/de not_active Withdrawn
- 2000-02-09 MX MXPA01008065A patent/MXPA01008065A/es unknown
- 2000-02-09 CA CA002359660A patent/CA2359660A1/en not_active Abandoned
- 2000-02-09 AT AT00907539T patent/ATE313553T1/de not_active IP Right Cessation
- 2000-02-09 AU AU29095/00A patent/AU2909500A/en not_active Abandoned
- 2000-02-09 EP EP00907539A patent/EP1144431B1/de not_active Expired - Lifetime
- 2000-02-09 PT PT00907539T patent/PT1144431E/pt unknown
- 2000-02-09 SK SK1130-2001A patent/SK11302001A3/sk unknown
- 2000-02-09 DK DK00907539T patent/DK1144431T3/da active
- 2000-02-09 ES ES00907539T patent/ES2255983T3/es not_active Expired - Lifetime
- 2000-02-09 HU HU0200055A patent/HUP0200055A3/hu unknown
- 2000-02-09 WO PCT/EP2000/001073 patent/WO2000047603A2/de not_active Ceased
- 2000-02-09 DE DE50011908T patent/DE50011908D1/de not_active Expired - Fee Related
- 2000-02-09 BR BR0008076-4A patent/BR0008076A/pt not_active IP Right Cessation
- 2000-02-09 PL PL00350360A patent/PL350360A1/xx not_active Application Discontinuation
- 2000-02-09 EE EEP200100412A patent/EE200100412A/xx unknown
- 2000-02-09 NZ NZ513409A patent/NZ513409A/xx unknown
- 2000-02-09 AR ARP000100553A patent/AR034392A1/es not_active Application Discontinuation
- 2000-02-09 YU YU57201A patent/YU57201A/sh unknown
- 2000-02-09 JP JP2000598520A patent/JP2002536455A/ja active Pending
- 2000-02-09 CN CN00803613A patent/CN1346364A/zh active Pending
- 2000-02-09 CZ CZ20012843A patent/CZ20012843A3/cs unknown
- 2000-02-09 HK HK02107553.2A patent/HK1046145A1/zh unknown
- 2000-02-09 KR KR1020017009989A patent/KR20010101822A/ko not_active Withdrawn
- 2000-02-09 EA EA200100828A patent/EA200100828A1/ru unknown
-
2001
- 2001-08-08 NO NO20013860A patent/NO20013860L/no not_active Application Discontinuation
- 2001-08-09 BG BG105804A patent/BG105804A/xx unknown
- 2001-09-06 ZA ZA200107388A patent/ZA200107388B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034392A1 (es) | Compuestos derivados de 3, 16-dihidroxi-estra-1,3,5(10)-trieno, empleo de los mismos y de partes estructurales de los mismos y composiciones farmaceuticas que los contienen | |
| MXPA02010066A (es) | Estratrienos sustituidos en 8beta-hidrocarbilo para uso como estrogenos selectivos. | |
| AR034091A1 (es) | Composiciones farmaceuticas que contienen un modulador selectivo del receptor de estrogeno; metodos de tratamiento y prevencion de la resistencia a la insulina y un compuesto modulador selectivo del receptor de estrogeno | |
| PE20220705A1 (es) | Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer | |
| PE55998A1 (es) | Derivados 19-nor-pregneno substituidos | |
| PE20020532A1 (es) | Derivados de naftaleno como agonistas del receptor canabinoide | |
| ECSP055576A (es) | Uso de derivados de ciclotiocarbamato en el tratamiento de las condiciones relacionadas con hormonas | |
| PA8582701A1 (es) | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf) | |
| ECSP055574A (es) | Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas. | |
| AR015222A1 (es) | Benzotiadiazoles, proceso para su preparacion, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento | |
| PE20080995A1 (es) | 18-metil-19-nor-androst-4-en-17,17-espiroeteres(18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen | |
| EA200100108A1 (ru) | Применение биогенных сульфаматов эстрогенов для гормонзаместительной терапии | |
| TR200401716T4 (tr) | Yeni üç yerdeğiştirme gruplu fenil türevleri ve analogları | |
| ATE272629T1 (de) | Benzothiophene | |
| AR040188A1 (es) | Estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva | |
| ES2131015B1 (es) | Nuevos derivados de 2-(3h)-oxazolona, procedimientos para su preparacion y su empleo en composiciones farmaceuticas. | |
| ES2282230T3 (es) | Formulacion anticonceptiva masculina que comprende noretisterona u undecanoato de testosterona. | |
| EA201000097A1 (ru) | 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов | |
| PE20070182A1 (es) | Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona | |
| PE20030186A1 (es) | Compuestos ciclicos fusionados como moduladores del receptor hormonal nuclear | |
| ES433982A1 (es) | Procedimiento para la preparacion de agentes antihelminti- cos. | |
| PE20020331A1 (es) | Compuesto esteroide 16alfa-sustituido como activador del receptor de estrogeno | |
| AR035590A1 (es) | Derivados 8 beta-sustituidos de 11beta-pentil- y 11beta-hexil-estra-1,3,5 (10)-trieno, las composiciones farmaceuticas que los contienen y el uso de estos derivados para preparar medicamentos | |
| PE20010581A1 (es) | Mesoprogestinas (modulares de receptores de progesterona) como componentes de composiciones utilizadas para la terapia de sustitucion hormonal (hrt) | |
| PE20001489A1 (es) | ESTEROIDE (14ß,17O)-17-(HIDROXIMETILO) CON ACTIVIDAD ANDROGENA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |